Pentixapharm's Q3 update reinforces the BUY case ahead of PANDA's start and potential partnering in 2027. Regulatory preparations have advanced, new oncology data strengthen the opportunity beyond primary aldosteronism (PA), and the convertible extension provides greater financial flexibility.
LÄS MER